Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Multiple Myeloma Research Consortium has initiated a Phase I/II study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Velcade for Injection for the treatment of relapsed multiple myeloma.
Subscribe to our email newsletter
This study sponsored by PDL BioPharma and conducted at the following Multiple Myeloma Research Consortium (MMRC) Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University of Chicago, Hackensack University Medical Center, and Roswell Park Cancer Institute, will evaluate the safety and efficacy of the combination in patients who have received one to three prior therapies.
Kathy Giusti, founder and CEO of MMRC, said: “The MMRC is proud to partner with PDL BioPharma to move this exciting new combination into the clinic. The MMRC’s facilitation of this trial underscores our commitment to advancing clinical trials of novel compounds and combination approaches that show the most potential in effectively treating patients.”